Prognosis
Drugmakers Clinch Deals to Boost Supplies of Pfizer’s Covid Pill
- Dozens of companies will make generic versions of therapy
- Larger supplies may not reach the world until next year
This article is for subscribers only.
About three dozen drugmakers will produce low-cost versions of Pfizer Inc.’s Covid-19 pill as part of an effort to expand supplies of the highly effective drug in lower-income regions.
Those companies, based in nations ranging from Bangladesh to Vietnam, will need to clear production and regulatory hurdles before the antiviral therapy can flow. A producer in Ukraine may join in making the drug, but hasn’t been able to sign an agreement because of Russia’s invasion.